Vertex, Inc. (VERX)

NASDAQ

$19.46

-$0.45 (2.24%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$19.36$19.94

Open $19.87

52 Week Range

$18.54$60.71

Previous Close $19.91

Market Cap3.11B

Volume1.14M

Avg Volume1.64M

P/E (TTM)-57.38

EPS (TTM)$-0.34

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Vertex, Inc.

DEC62025

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Source: Business Wire•9 days ago

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sick...

DEC52025

Vertex and CPA.com Announce AI-Driven Expansion of Tax Compliance Services for Accounting Firms

Source: GlobeNewsWire•10 days ago

KING OF PRUSSIA, Pa., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, and CPA.com, the trusted partner in accounting and finance transformation, today annou...

NOV192025

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Source: Business Wire•26 days ago

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi's 2025 Global Healthcare Conference. Charlie Wagner, Chief Operating and Financial Officer, and David Altshuler, Chief Scient...

NOV82025

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Source: Business Wire•37 days ago

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society ...

NOV32025

Vertex Reports Third Quarter 2025 Financial Results

Source: Business Wire•42 days ago

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance. “Vertex delivered strong results ...

NOV32025

Vertex Announces Third Quarter 2025 Financial Results and $150 Million Class A Common Stock Repurchase Program

Source: GlobeNewsWire•42 days ago

KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its third quarter ended September 30, 2025 and...

OCT302025

Vertex Appoints New Leader in Europe to Advance Product Innovation and Strengthen Compliance

Source: GlobeNewsWire•47 days ago

Industry expert Ralf Gärtner joins as SVP and Regional Manager to spearhead Vertex's global operations Industry expert Ralf Gärtner joins as SVP and Regional Manager to spearhead Vertex's global operations...

OCT272025

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Source: Business Wire•49 days ago

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside cha...

OCT172025

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Source: Business Wire•59 days ago

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonis...

OCT142025

Vertex Achieves Oracle Validated Integration for Delivering a Proven, Repeatable Integration for Oracle's ERP Solution

Source: GlobeNewsWire•62 days ago

Vertex Accelerator for Oracle's ERP offering gives customers an embedded, push-button integration with a powerful user interface, flexible mapping and accurate tax calculation to accelerate time to value. Vertex Accelerator for Oracle's ERP offering ...